128 related articles for article (PubMed ID: 38469695)
1. Decoding selectivity: computational insights into AKR1B1 and AKR1B10 inhibition.
Liu M; Qin X; Li J; Jiang Y; Jiang J; Guo J; Xu H; Wang Y; Bi H; Wang Z
Phys Chem Chem Phys; 2024 Mar; 26(12):9295-9308. PubMed ID: 38469695
[TBL] [Abstract][Full Text] [Related]
2. Repurposing of Strychnine as the Potential Inhibitors of Aldo-keto Reductase Family 1 Members B1 and B10: Computational Modeling and Pharmacokinetic Analysis.
Sarfraz M; Aziz M; Afzal S; Channar PA; Alsfouk BA; Kandhro GA; Hassan S; Sultan A; Hamad A; Arafat M; Qaiser MN; Ahmed A; Siddique F; Ejaz SA
Protein J; 2024 Apr; 43(2):207-224. PubMed ID: 37940790
[TBL] [Abstract][Full Text] [Related]
3. Human and rodent aldo-keto reductases from the AKR1B subfamily and their specificity with retinaldehyde.
Ruiz FX; Moro A; Gallego O; Ardèvol A; Rovira C; Petrash JM; Parés X; Farrés J
Chem Biol Interact; 2011 May; 191(1-3):199-205. PubMed ID: 21329680
[TBL] [Abstract][Full Text] [Related]
4. Engineering aldo-keto reductase 1B10 to mimic the distinct 1B15 topology and specificity towards inhibitors and substrates, including retinoids and steroids.
Giménez-Dejoz J; Weber S; Fernández-Pardo Á; Möller G; Adamski J; Porté S; Parés X; Farrés J
Chem Biol Interact; 2019 Jul; 307():186-194. PubMed ID: 31028727
[TBL] [Abstract][Full Text] [Related]
5. Aldo Keto Reductases AKR1B1 and AKR1B10 in Cancer: Molecular Mechanisms and Signaling Networks.
Banerjee S
Adv Exp Med Biol; 2021; 1347():65-82. PubMed ID: 33945128
[TBL] [Abstract][Full Text] [Related]
6. The aldo-keto reductases (AKRs): Overview.
Penning TM
Chem Biol Interact; 2015 Jun; 234():236-46. PubMed ID: 25304492
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Phenylcarbamoylazinane-1,2,4-Triazole Amides Derivatives as the Potential Inhibitors of Aldo-Keto Reductases (AKR1B1 & AKRB10): Potential Lead Molecules for Treatment of Colon Cancer.
Saeed A; Ejaz SA; Sarfraz M; Tamam N; Siddique F; Riaz N; Qais FA; Chtita S; Iqbal J
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807227
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B; Kisiela M; Wsól V; Maser E
Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737
[TBL] [Abstract][Full Text] [Related]
9. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
[TBL] [Abstract][Full Text] [Related]
10. Characterization of AKR1B16, a novel mouse aldo-keto reductase.
Giménez-Dejoz J; Weber S; Barski OA; Möller G; Adamski J; Parés X; Porté S; Farrés J
Chem Biol Interact; 2017 Oct; 276():182-193. PubMed ID: 28322781
[TBL] [Abstract][Full Text] [Related]
11. Selective Inhibition of Human AKR1B10 by
Seliger JM; Cicek SS; Witt LT; Martin HJ; Maser E; Hintzpeter J
Molecules; 2018 Nov; 23(11):. PubMed ID: 30469331
[TBL] [Abstract][Full Text] [Related]
12. Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia.
Kikuya M; Furuichi K; Hirao T; Endo S; Toyooka N; Ito K; Aoki S
J Pharmacol Sci; 2021 Sep; 147(1):1-8. PubMed ID: 34294359
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
Cousido-Siah A; Ruiz FX; Mitschler A; Porté S; de Lera ÁR; Martín MJ; Manzanaro S; de la Fuente JA; Terwesten F; Betz M; Klebe G; Farrés J; Parés X; Podjarny A
Acta Crystallogr D Biol Crystallogr; 2014 Mar; 70(Pt 3):889-903. PubMed ID: 24598757
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10.
Soda M; Hu D; Endo S; Takemura M; Li J; Wada R; Ifuku S; Zhao HT; El-Kabbani O; Ohta S; Yamamura K; Toyooka N; Hara A; Matsunaga T
Eur J Med Chem; 2012 Feb; 48():321-9. PubMed ID: 22236472
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of steroidal derivatives as selective inhibitors of AKR1B10.
Zhang W; Wang L; Zhang L; Chen W; Chen X; Xie M; Yan G; Hu X; Xu J; Zhang J
Steroids; 2014 Aug; 86():39-44. PubMed ID: 24793566
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
Gallego O; Ruiz FX; Ardèvol A; Domínguez M; Alvarez R; de Lera AR; Rovira C; Farrés J; Fita I; Parés X
Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20764-9. PubMed ID: 18087047
[TBL] [Abstract][Full Text] [Related]
17. Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer.
Taskoparan B; Seza EG; Demirkol S; Tuncer S; Stefek M; Gure AO; Banerjee S
Cell Oncol (Dordr); 2017 Dec; 40(6):563-578. PubMed ID: 28929377
[TBL] [Abstract][Full Text] [Related]
18. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
Zhao HT; Soda M; Endo S; Hara A; El-Kabbani O
Eur J Med Chem; 2010 Sep; 45(9):4354-7. PubMed ID: 20538382
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of compound selectivity of aldo-keto reductases using differential scanning fluorimetry.
Kabir A; Endo S; Toyooka N; Fukuoka M; Kuwata K; Kamatari YO
J Biochem; 2017 Feb; 161(2):215-222. PubMed ID: 28003428
[TBL] [Abstract][Full Text] [Related]
20. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A
Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]